Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age2+
SponsorCatalyst Pharmaceuticals, Inc.

About this trial

The goal of this study is to collect additional information on the safety of long-term treatment with AGAMREE® and to explore long-term clinical impact of AGAMREE® on quality of life, as assessed by standardized patient-reported outcome measures (QoL questionnaires) in male patients aged 2 years and older with Duchenne muscular dystrophy (DMD).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient or parent/legal guardian is willing and able to provide written informed consent once the nature of the registry has been explained and prior to the start of any registry-related procedures.

Patient and/or parent/guardian are willing and able to complete QoL questionnaires.

Male patients at least 2 years old.

Confirmed diagnosis of DMD (via genetic testing or muscle biopsy with absent dystrophin staining to anti- dystrophin antibodies 3, 1, or 2, or dystrophin immunohistochemistry or western blot).

Disqualifiers

None

Trial population

Male patients at least 2 years old with confirmed diagnosis of DMD (via genetic testing or muscle biopsy with absent dystrophin staining to anti-dystrophin antibodies 3, 1, or 2, or dystrophin immunohistochemistry or western blot).

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Vamorolone

    Drug

    Study treatment is AGAMREE®, which is commercially available as an oral suspension.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Change in Height z-score

Standing height in participants 2 years of age and older will be measured using a stadiometer mounted at a right angle between a level floor and against a straight, vertical surface. When transitioning from recumbent length to standing height measurements in participants between 2 to 3 years of age, measure both length and height. If collecting standing height measurements is not feasible, height will be estimated using arm span measurements. To estimate the height, the arm span will be measured from fingertip to fingertip with arms fully extended horizontally. The same standardized technique will be used at all study visits.

Time frame
At Enrollment Visit (baseline), and at each Yearly Follow-up Visit (for up to 5 years).
2

Change in BMI z-score

Weight will be measured according to the site's standard of care procedures. For ambulatory patients, this typically involves a standing scale; for non-ambulatory patients, a wheelchair or bed scale may be used. Sites should document the method used at each visit.

Time frame
At Enrollment Visit (baseline), and each Yearly Follow-up Visit (for up to 5 years)
3

Change in North Star Ambulatory Assessment from baseline

The North Star Ambulatory Assessment is a clinical assessment scale specifically designed to measure functional ability in ambulant male patients with DMD. The North Star Ambulatory Assessment consists of 17 scored items and 2 timed tests, including the Time to Run/Walk Test and the Time to Stand Test. The Time to Run/Walk Test measures the time (in seconds) that it takes the patient to run or walk 10 meters. The Time to Stand Test measures the time (in seconds) required for the patient to stand in an erect position from supine (floor). Patients should be barefoot and comfortably clothed. North Star Ambulatory Assessment score range is 0 to 34, with higher scores indicating better ambulatory function.

Time frame
At Enrollment visit, and each Yearly Follow-up Visit (for up to 5 years).
4

Change in Performance of Upper Limb from baseline

The Performance of Upper Limb assessment is an observer-rated measure of upper-limb function in individuals with Duchenne muscular dystrophy. It includes an entry item to determine the participant's starting functional level and a series of tasks evaluating shoulder, mid-level (elbow), and distal (wrist/hand) abilities. Total scores reflect the participant's ability to perform defined functional movements, with higher scores indicating better function.

Time frame
At Enrollment Visit, at each Yearly Follow-up Visit (for up to 5 years).

Secondary outcomes

1

Changes in Duchenne Muscular Dystrophy Quality of Life questionnaire score

Duchenne Muscular Dystrophy Quality of Life questionnaire is a patient-reported outcome measure designed to assess how Duchenne muscular dystrophy affects physical, emotional, and social aspects of daily life. Duchenne Muscular Dystrophy Quality of Life questionnaire proxy report will be completed by a parent/guardian for patients aged 7 years and older. For patients aged 10 years and older, a self-report will be completed by the patient, and, if feasible, a proxy report will also be completed by the parent or guardian.

Time frame
At Enrollment Visit (baseline) and at each Yearly Follow-up Visit for up to 5 years.
2

Change in Patient Reported Outcome Measure for the Upper Limb score

Patient Reported Outcome Measure for the Upper Limb is a questionnaire for young males/children with DMD from the age of 7 years. The PROM UL will be completed by parent/legal guardian up to the age of 16 years and by the patient from the age of 17 years. It consists of 32 items covering four domains of activities of daily living: (1) food, (7 items, max score 14); (2) self-care, (8 items, max score 16); (3) household and environment, (6 items, max score 12); (4) leisure and communication, (11 items, max score 22). For each question, the patients and/or their parent/legal guardian are asked to report their perceived difficulty in performing the activity on a 3-level scale: Cannot do (0); Can do with difficulty (1); Can do easily (2). The maximum total score is 64, with higher score indicating better function.

Time frame
At Enrollment Visit (baseline), and each Yearly Follow-Up Visit (for up to 5 years).

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Catalyst Pharmaceuticals, Inc.

Lead sponsor

ICON plc

Collaborator

Veeva Systems

Collaborator

Children's Hospital of Eastern Ontario

Collaborator

Medpace, Inc.

Collaborator